Pharma BD Deal Intelligence
Not an acquisition of Exelixis at all — two small BMS licensing deals ($60M combined upfront, not $0.6B) on TGR5/ROR programs that both lapsed unproductively within three years, with zero drugs ever reaching the clinic-to-market finish line under BMS.
Full analysis, sources & comparables →On October 8, 2010, Exelixis entered into new agreements with Bristol-Myers Squibb... Exelixis will grant to Bristol-Myers Squibb a license to its…
Coverage framed the dual deals as Exelixis monetizing non-oncology research while keeping XL184 (cabozantinib) post-XL184 termination — a strategic re-focusing…
BMS paid Exelixis $60M upfront across two preclinical deals — exclusive worldwide TGR5 license (up to $250M milestones) and an ROR antagonist collaboration (up…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Exelixis licensed exclusive TGR5 agonist program ($250M milestones) and entered ROR antagonist collaboration ($255M milestones) with BMS for total $60M combined upfront. Followed XL184 codevelopment termination.
Not an acquisition of Exelixis at all — two small BMS licensing deals ($60M combined upfront, not $0.6B) on TGR5/ROR programs that both lapsed unproductively within three years, with zero drugs ever reaching the clinic-to-market finish line under BMS.
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Bristol-Myers Squibb Company / Exelixis, Inc. (TGR5 + ROR programs) (this deal) | 2010 | $565M | 22 |
| Bristol-Myers Squibb Company / Medarex Inc. | 2009 | $2.4B | 92 |
| Bristol-Myers Squibb Company / Celgene Corporation | 2019 | $74.0B | 77 |
| Bristol-Myers Squibb Company / MyoKardia Inc. | 2020 | $13.1B | 76 |
| Bristol-Myers Squibb Company / Karuna Therapeutics | 2023 | $14.0B | 76 |
| Bristol-Myers Squibb Company / Ono Pharmaceutical Co., Ltd. | 2011 | — | 76 |
| Bristol-Myers Squibb Company / SystImmune Inc. | 2023 | $8.4B | 71 |
← Browse all deals · How we score deals
More: 2010 deals · Bristol-Myers Squibb Company deals · Immunology deals